Dexcom (DXCM) Receivables (2010 - 2026)

Dexcom (DXCM) has reported Receivables for 17 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables fell 6.46% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 6.46% decrease from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 19.7% from the prior year.
• Receivables was $1.3 billion for Q2 2026 at Dexcom, up from $1.1 billion in the prior quarter.
• Over five years, Receivables peaked at $1.4 billion in Q2 2025 and troughed at $554.8 million in Q1 2022.
• A 5-year average of $938.5 million and a median of $990.0 million in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables surged 53.12% in 2024 and fell 6.46% in 2026, its largest moves.
• Over 5 years, Receivables stood at $729.6 million in 2022, then soared by 35.86% to $991.2 million in 2023, then advanced by 3.92% to $1.0 billion in 2024, then climbed by 19.7% to $1.2 billion in 2025, then rose by 3.62% to $1.3 billion in 2026.
• The last three Receivables figures came in at $1.3 billion (Q2 2026), $1.1 billion (Q1 2026), and $1.2 billion (Q4 2025), per Business Quant data.